In this poster, we showcase how Quantitative Systems Pharmacology (QSP) modeling guided the development of KK2269, a bispecific antibody targeting CD40 and EpCAM to enhance tumor selectivity. Using a modular immuno-oncology model, Certara simulated combination therapies with docetaxel, optimizing dosing strategies for solid tumor treatments. The model accurately predicted pharmacokinetics, immune activation, and therapy efficacy, demonstrating its value in advancing cancer treatments.